Skip to main content
. 2011 May 1;3(3):273–288. doi: 10.4161/mabs.3.3.15188

Figure 3.

Figure 3

Dual inhibitory activities of EI-04 on EGFR and IGF-1R. (A) Blockade of europium-labeled EGF binding to EGFR-Fc by EI-04 in comparison to various anti-EGFR mAbs. (B) Blockade of a constant level of IGF-1 (25 nM, left part) or IGF-2 (60 nM, right part) binding to biotin-hIGF-1R-Fc by EI-04 in comparison to anti-IGF-1R mAb C06. (C) Inhibition of EGF-induced EGFR phosphorylation in H322M tumor cells by EI-04 in comparison to anti-EGFR mAb M60-A02. Serum-starved cells were treated with EI-04 or M60-A02, or control IgG (ctrl Ab) for 1 h followed by stimulation with 100 ng/ml of EGF for 15 min. Phospho-EGFR and total EGFR were analyzed by western blot. (D) Inhibition of IGF-1-induced IGF-1R phosphorylation in H322M tumor cells by EI-04 in comparison to anti-IGF-1R mAb C06. Serum-starved cells were treated with EI-04 or C06 or control IgG (ctrl Ab) for 1 h followed by stimulation with 200 ng/ml of IGF-1 for 20 min. Phospho-IGF-1R and total IGF-1R were analyzed by western blot.